FGFR1 amplification has been identified in 10–20% of patients with non-small cell lung cancer whereas 4–10% of primary gastric cancers and approximately 75% of bladder cancers harbor FGFR2 amplification and FGFR3 mutations, respectively (7–10). This evidence concerns the gene FGFR3 and non-small cell lung carcinoma.